Pfizer concludes phase 3 study of COVID-19 vaccine candidate, says it's 95% effective

Yoshita Singh
·2-min read

New York, Nov 18 (PTI) Global drugmakers Pfizer and BioNTech said on Wednesday their COVID-19 vaccine candidate is 95 per cent effective, including in people over 65 years of age, a major announcement coming just two days after Moderna said its virus vaccine has an efficacy rate of 94.5 per cent.

Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.

Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.

This week, leading biotechnology company Moderna said its COVID-19 vaccine had shown to be 94.5 per cent effective. Earlier this month, Pfizer and Biontech had said their COVID-19 vaccine candidate was found to be more than 90 per cent effective in preventing COVID-19 in participants.

Analysis of the data indicates a vaccine efficacy rate of 95 per cent in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose.

The company said the first primary objective analysis is based on 170 cases of COVID-19, of which 162 cases of coronavirus were observed in the placebo group while 8 cases in the BNT162b2 group.

Vaccine efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94 per cent.

There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.

'The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,' said Dr Albert Bourla, Pfizer Chairman and CEO.

'With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,' Bourla said. PTI YAS MRJ AKJ MRJ